MetaCap

Perspective Therapeutics (CATX) vs Upstream Bio (UPB)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Perspective Therapeutics (CATX) has outperformed Upstream Bio (UPB) over the past year, losing 63.9% versus a loss of 93.8%. Perspective Therapeutics is the larger company by market cap ($91.0 million vs $87.2 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CATX-63.93%UPB-93.78%
+184%+38%-107%
Nov 21, 20251 yearNov 20, 2026
CATX-94.05%UPB-92.77%
+48%-26%-101%
Oct 7, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CATX versus UPB key metrics
MetricCATXUPB
Share price$0.7538$1.59
Market cap$91.03M$87.15M
1-day change-3.85%-20.50%
YTD return-72.59%-94.14%
1-year return-63.93%-93.78%
5-year return-84.62%—
EPS (TTM)$-1.25$-3.01
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$2.85M
Revenue growth (YoY)—+20.42%
Net income (latest FY)$-103.12M$-143.44M
Operating margin—-5618.82%
Net margin—-5026.03%
52-week high$6.16$33.68
52-week low$0.73$1.56
Distance from 52-week high-87.76%-95.28%
Analyst consensusstrong_buybuy
Avg. price target upside+1188.14%+1245.91%
Average volume2.70M1.01M
Shares outstanding120.76M54.81M
Employees16375
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • CATX has outperformed UPB by 29.8 percentage points over the past year.

About Perspective Therapeutics

CATX stock →

Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta emitting therapy; VMT01, which is in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma; and PSV359, a targeted alpha therapy targeting fibroblast activation protein alpha.

Health Care · Biotechnology: Pharmaceutical Preparations · 163 employees

About Upstream Bio

UPB stock →

Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease.

Health Care · Biotechnology: Pharmaceutical Preparations · 75 employees

CATX vs UPB FAQ

Which is bigger, Perspective Therapeutics or Upstream Bio?

Perspective Therapeutics (CATX) is larger, with a market capitalization of $91.03M compared with $87.15M for Upstream Bio (UPB).

Which stock has performed better over the past year, CATX or UPB?

CATX returned -63.93% over the past 12 months, compared with -93.78% for UPB (price return, excluding dividends). Past performance does not predict future results.

Are Perspective Therapeutics and Upstream Bio in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons